| Business Summary | | VidaMed,
Inc.
designs,
develops
and
markets
technologically
and
clinically
advanced
systems
for
urological
conditions.
Its
focus
is
the
treatment
of
the
enlarged
prostate
known
as
benign
prostatic
hyperplasia
(BPH).
The
Company's
primary
product,
the
patented
Transurethral
Needle
Ablation
(TUNA)
system,
is
designed
to
offer
a
safe,
cost-effective,
minimally
invasive
treatment
for
BPH
and
an
alternative
to
drug
therapy
and
major
surgery.
The
TUNA
procedure
is
designed
to
restore
and
improve
urinary
flow
and
be
performed
in
a
physician's
office
or
other
outpatient
setting.
The
TUNA
system
delivers
low
levels
of
radio
frequency
energy
precisely
into
prostate
tissue
to
relieve
the
symptoms
associated
with
an
enlarged
prostate.
The
principal
components
of
the
TUNA
system
are
the
radio
frequency
generator,
a
reusable
hand-piece
and
telescope
and
a
single-use
disposable
catheter
needed
for
each
procedure. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | VidaMed,
Inc.
designs,
develops,
manufactures
and
markets
technologically
and
clinically
advanced,
cost
effective
systems
for
urological
conditions,
with
an
initial
focus
on
the
treatment
of
the
enlarged
prostate
or
benign
prostatic
hyperplasia.
For
the
six
months
ended
6/30/01,
revenues
rose
6%
to
$5.2
million.
Net
loss
rose
18%
to
$5.2
million.
Results
reflect
an
increase
in
procedure
volume,
offset
by
lower
margins
due
to
lower
average
prices. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Randy Lindholm, 45 Chairman,
Pres, CEO | $1.0M | John Howe, 48 CFO,
VP-Fin. | 241K | Stephen Williams, 48 COO,
VP-Operations | 145K | Lewis Chapman, 50 VP
of Global Marketing and Sales, CBO | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|